Evaluation of a new line probe assay for rapid identification of gyrA mutations in Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 7, 2005, Pages 2928-2933

  Giannoni, Federico ^a   Iona, Elisabetta ^a   Sementilli, Federica ^a   Brunori, Lara ^a   Pardini, Manuela ^a   Migliori, Giovanni Battista ^b   Orefici, Graziella ^a   Fattorini, Lanfranco ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ASPARAGINE; ASPARTIC ACID; CIPROFLOXACIN; DIGOXIGENIN; GATIFLOXACIN; GLYCINE; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PROLINE; PYROXYLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SERINE; SPARFLOXACIN; THREONINE; VALINE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASSAY; BACTERIAL GENE; CODON; COLONY FORMING UNIT; CONTROLLED STUDY; EVALUATION; GENE MUTATION; GENETIC POLYMORPHISM; GYRA GENE; HUMAN; HYBRIDIZATION; IN VITRO STUDY; LINE PROBE ASSAY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; OLIGONUCLEOTIDE PROBE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SPUTUM CULTURE;

ANTI-BACTERIAL AGENTS; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; NUCLEIC ACID HYBRIDIZATION; OFLOXACIN; OLIGONUCLEOTIDE PROBES; TIME FACTORS;

EID: 21444443184     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.7.2928-2933.2005     Document Type: Article

References (34)

1. Alangaden, G. J., E. K. Manavathu, S. B. Vakulenko, N. M. Zvonok, and S. A. Lerner. 1995. Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients. Antimicrob. Agents Chemother. 39:1700-1703.
2. Aubry, A., X. S. Pan, L. M. Fisher, V. Jarlier, and E. Cambau. 2004. Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob. Agents Chemother. 48:1281-1288.
3. Blumberg, H. M., W. J. Burman, R. E. Chaisson, C. L. Daley, S. C. Etkind, L. N. Friedman, P. Fujiwara, M. Grzemska, P. C. Hopewell, M. D. Iseman, R. M. Jasmer, V. Koppaka, R. I. Menzies, R. J. O'Brien, R. R. Reves, L. B. Reichman, P. M. Simone, J. R. Starke, A. A. Vernon, et al. 2003. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603-662.
4. Boom, R., C. J. Sol, M. M. Salimans, C. L. Jansen, P. M. Wertheim-van Dillen, and J. van der Noordaa. 1990. Rapid and simple method for purification of nucleic acids. J. Clin. Microbiol. 28:495-503.
5. Bryskier, A., and J. Lowther. 2002. Fluoroquinolones and tuberculosis. Expert Opin. Investig. Drugs 11:233-258.
6. Chan, E. D., V. Laurel, M. J. Strand, J. F. Chan, M. L. Huynh, M. Goble, and M. D. Iseman. 2004. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 169:1103-1109.
7. Cheng, A. F., W. W. Yew, E. W. Chan, M. L. Chin, M. M. Hui, and R. C. Chan. 2004. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob. Agents Chemother. 48:596-601.
8. Crofton, J., P. Chaulet, D. Maher, J. Grosset, W. Harris, N. Horne, M. Iseman, and B. Watt. 1997. Guidelines for the management of drug-resistant tuberculosis. World Health Organization, Geneva, Switzerland.
9. Fattorini, L., E. Iona, M. L. Ricci, O. F. Thoresen, G. Orru, M. R. Oggioni, E. Tortoli, C. Piersimoni, P. Chiaradonna, M. Tronci, G. Pozzi, and G. Orefici. 1999. Activity of 16 antimicrobial agents against drug-resistant strains of Mycobacterium tuberculosis. Microb. Drug Resist. 5:265-270.
10. Fattorini, L., D. Tan, E. Iona, M. Mattei, F. Giannoni, L. Brunori, S. Recchia, and G. Orefici. 2003. Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice. Antimicrob. Agents Chemother. 47:360-362.
11. Ginsburg, A. S., J. H. Grosset, and W. R. Bishai. 2003. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect. Dis. 3:432-442.
12. Ginsburg, A. S., S. C. Woolwine, N. Hooper, W. H. Benjamin, Jr., W. R. Bishai, S. E. Dorman, T. R. Sterling, and S. R. Timothy. 2003. The rapid development of fluoroquinolone resistance in M. tuberculosis. N. Engl. J. Med. 349:1977-1978.
13. Grimaldo, E. R., T. E. Tupasi, A. B. Rivera, M. I. Quelapio, R. C. Cardano, J. O. Derilo, and V. A. Belen. 2001. Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant Mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines. Int. J. Tuberc. Lung Dis. 5:546-550.
14. Kox, L. F., J. van Leeuwen, S. Knijper, H. M. Jansen, and A. H. Kolk. 1995. PCR assay based on DNA coding for 16S rRNA for detection and identification of mycobacteria in clinical samples. J. Clin. Microbiol. 33:3225-3233.
15. Lee, A. S., L. L. Tang, I. H. Lim, and S. Y. Wong. 2002. Characterization of pyrazinamide and ofloxacin resistance among drug resistant Mycobacterium tuberculosis isolates from Singapore. Int. J. Infect. Dis. 6:48-51.
16. Master, R. N. 1992. Mycobactcriology, p. 3.0.1-3.1.6.4. In H. D. Isenberg (ed.), Clinical microbiology procedures handbook. American Society for Microbiology, Washington, D.C.
17. Metchock, B. G., F. S. Nolte, and R. J. Wallace, Jr. 1999. Mycobacterium, p. 399-437. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 7th ed. American Society for Microbiology, Washington, D.C.
18. NCCLS. 2003. Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes; approved standards. Vol. 23, no. 18. M24-A. NCCLS, Wayne, Pa.
19. Perlman, D. C., W. M. El Sadr, L. B. Heifets, E. T. Nelson, J. P. Matts, K. Chirgwin, N. Salomon, E. E. Telzak, O. Klein, B. N. Kreiswirth, J. M. Musser, R. Hafner, et al. 1997. Susceptibility to levorloxacin of Myocobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. AIDS 11:1473-1478.
20. Rossau, R., H. Traore, H. De Beenhouwer, W. Mijs, G. Jannes, P. De Rijk, and F. Portaels. 1997. Evaluation of the INNO-LiPA Rif. TB assay, a reverse hybridization assay for the simultaneous detection of Mycobacterium tuberculosis complex and its resistance to rifampin. Antimicrob. Agents Chemother. 41:2093-2098.
21. Saiki, R. K., P. S. Walsh, C. H. Levenson, and H. A. Erlich. 1989. Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes. Proc. Natl. Acad. Sci. USA 86:6230-6234.
22. Siddiqi, N., M. Shamim, S. Hussain, R. K. Choudhary, N. Ahmed, Prachee, S. Banerjee, G. R. Savithri, M. Alam, N. Pathak, A. Amin, M. Hanief, V. M. Katoch, S. K. Sharma, and S. E. Hasnain. 2002. Molecular characterization of multidrug-resistant isolates of Mycobacterium tuberculosis from patients in North India. Antimicrob. Agents Chemother. 46:443-450.
23. Sindelar, G., X. Zhao, A. Liew, Y. Dong, T. Lu, J. Zhou, J. Domagala, and K. Drlica. 2000. Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria. Antimicrob. Agents Chemother. 44:3337-3343.
24. Sougakoff, W., N. Lemaitre, E. Cambau, M. Szpytma, V. Revel, and V. Jarlier. 1997. Nonradioactivc single-strand conformation polymorphism analysis for detection of fluoroquinolone resistance in mycobacteria. Eur. J. Clin. Microbiol. Infect. Dis. 16:395-398.
25. Sreevatsan, S., X. Pan, K. E. Stockbauer, N. D. Connell, B. N. Kreiswirth, T. S. Whittam, and J. M. Musser. 1997. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionary recent global dissemination. Proc. Natl. Acad. Sci. USA 94:9869-9874.
26. Sullivan, E. A., B. N. Kreiswirth, L. Palumbo, V. Kapur, J. M. Musser, A. Ebrahimzadeh, and T. R. Frieden. 1995. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet 345:1148-1150.
27. Takiff, H. E., L. Salazar, C. Guerrero, W. Philipp, W. M. Huang, B. Kreiswirth, S. T. Cole, W. R. Jacobs, Jr., and A. Telenti. 1994. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob. Agents Chemother. 38:773-780.
28. Tortoli, E., P. Cichero, C. Piersimoni, M. T. Simonetti, G. Gesu, and D. Nista. 1999. Use of BACTEC MGIT 960 for recovery of mycobacteria from clinical specimens: multicenter study. J. Clin. Microbiol. 37:3578-3582.
29. Veziris, N., C. Truffot-Pernot, A. Aubry, V. Jarlier, and N. Lounis. 2003. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrob. Agents Chemother. 47:3117-3122.
30. Watterson, S. A., S. M. Wilson, M. D. Yates, and F. Drobniewski. 1998. Comparison of three molecular assays for rapid detection of rifampin resistance in Mycobacterium tuberculosis. J. Clin. Microbiol. 36:1969-1973.
31. Williams, K. J., R. Chan, and L. J. Piddock. 1996. gyrA of ofloxacin-resistant clinical isolates of Mycobacterium tuberculosis from Hong Kong. J. Antimicrob. Chemother. 37:1032-1034.
32. Xu, C., B. N. Kreiswirth, S. Sreevatsan, J. M. Musser, and K. Drlica. 1996. Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis. J. Infect. Dis. 174:1127-1130.
33. Zhang, Y., and A. Telenti. 2000. Genetics of drug resistance in Mycobacterium tuberculosis, p. 235-254. In G. F. Hatfull and W. R. Jacobs (ed.), Molecular genetics of mycobacteria. American Society for Microbiology, Washington, D.C.
34. Zhou, J., Y. Dong, X. Zhao, S. Lee, A. Amin, S. Ramaswamy, J. Domagala, J. M. Musser, and K. Drlica. 2000. Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations. J. Infect. Dis. 182:517-525.